FQI 1

CAS No. 599151-35-6

FQI 1( —— )

Catalog No. M34886 CAS No. 599151-35-6

FQI 1 is a selective late-stage SV40 factor (LSF) inhibitor with anticancer activity that exerts its antiproliferative activity by disrupting the mitotic spindle.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 50 In Stock
2MG 29 In Stock
5MG 46 In Stock
10MG 73 In Stock
25MG 150 In Stock
50MG 239 In Stock
100MG 347 In Stock
200MG Get Quote In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    FQI 1
  • Note
    Research use only, not for human use.
  • Brief Description
    FQI 1 is a selective late-stage SV40 factor (LSF) inhibitor with anticancer activity that exerts its antiproliferative activity by disrupting the mitotic spindle.
  • Description
    FQI1 is a Late SV40 Factor (LSF) inhibitor. FQI1 inhibits cell proliferation, with IC50s of 3, 0.79, 6.3 μM for NIH/3T3, HeLa, A549 cells. FQI1 can be used for cancer research.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    Others
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    599151-35-6
  • Formula Weight
    311.33
  • Molecular Formula
    C18H17NO4
  • Purity
    >98% (HPLC)
  • Solubility
    In Vitro:?DMSO : 100 mg/mL (321.20 mM; Ultrasonic )
  • SMILES
    CCOc1ccccc1C1CC(=O)Nc2cc3OCOc3cc12
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Ulla Hansen, et al. Inhibitors of late sv40 factor (lsf) as cancer chemotherapeutics. WO2012050985.
molnova catalog
related products
  • Adipic acid

    From an industrial perspective, it is the most important dicarboxylic acid, mainly as a precursor for the production of nylon.

  • coreopsin

    Coreopsin is one of the main components from Coreopsis tinctoria Nutt. Flower(CTF). CTF has been used traditionally in China for treating hypertension and diabetes as well as reducing body weight and blood fat.

  • Rilematovir

    JNJ-678 is a novel inhibitor of the fusion protein. JNJ-678 shows the potential for respiratory syncytial virus (RSV) treatment.